Karuna Therapeutics, Inc. Common Stock
KRTX
KRTX was delisted on the 15th of March, 2024.
328 hedge funds and large institutions have $12B invested in Karuna Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 110 funds opening new positions, 105 increasing their positions, 87 reducing their positions, and 36 closing their positions.
333% more funds holding in top 10
Funds holding in top 10: 6 → 26 (+20)
206% more first-time investments, than exits
New positions opened: 110 | Existing positions closed: 36
87% more capital invested
Capital invested by funds: $6.46B → $12B (+$5.59B)
28% more funds holding
Funds holding: 256 → 328 (+72)
21% more repeat investments, than reductions
Existing positions increased: 105 | Existing positions reduced: 87
20% more call options, than puts
Call options by funds: $277M | Put options by funds: $231M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$202M |
| 2 |
HI
HBK Investments
Dallas,
Texas
|
+$124M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$101M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$81.5M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$65.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$541M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$191M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$150M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$55M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
-$43.4M |
KRTX Hedge Fund Activity: Q4 2023 in Review
328 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q4 2023, worth a combined $12B — up 87% from $6.46B a quarter earlier.
Buyers outnumbered sellers: 110 funds opened new KRTX positions and 36 closed out — a net gain of 74 holders — while 105 added to existing stakes and 87 trimmed.
The largest buyer was Pentwater Capital Management, adding an estimated $202M. The largest seller was Fidelity Investments, cutting an estimated $541M.
- 328 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q4 2023, up from 256 in Q3 2023.
- Funds reported $12B of Karuna Therapeutics, Inc. Common Stock stock for Q4 2023, up 87% quarter-over-quarter.
- 110 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q4 2023 and 36 closed out, a net change of +74 holders.
- The largest Karuna Therapeutics, Inc. Common Stock buyer in Q4 2023 was Pentwater Capital Management, an estimated $202M added.
- The largest Karuna Therapeutics, Inc. Common Stock seller in Q4 2023 was Fidelity Investments, an estimated $541M sold.
Based on aggregated 13F filings for Q4 2023.